Focused Ultrasound Therapy
Focused ultrasound is a rapidly evolving, therapeutic technology that could transform the quality of life and decrease the cost of care for patients with COVID. This novel technology focuses beams of ultrasound energy precisely and accurately on targets deep in the body without damaging surrounding normal tissue.
How it Works
Where the beams converge, low intensity focused ultrasound enhances the delivery of tissue plasminogen activator (TPA) to disrupt the misfolded Amyloid microclots that are associated with this disease. These clots can cause thrombotic disruption, impaired oxygenation, and chronic inflammation in preclinical models. This impact is being pursued in COVID, but it also may be relevant in Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Diabetes and others. While significant work has been accomplished, there is still much to be done before this technology will be widely available.
The primary options for treatment these microclots are limited to unenhanced delivery of these blood thinners.
For certain patients, focused ultrasound could provide a non-invasive addition to the existing treatment.
Advantages
- Focused ultrasound is non-invasive, so it does not carry added concerns like surgical wound healing or infection.
- Focused ultrasound can reach the desired target without damaging surrounding tissue.
- It can be repeated, if necessary.
Clinical Trials
At the present time, there are no clinical trials recruiting patients for focused ultrasound treatment of COVID.
The Foundation updates these pages regularly, but with the increasing number of clinical trials, we want to be sure that our audience has the latest information available. Therefore, we also added the website search information for the above trials. If you click here, it will take you to the latest information available from https://www.clinicaltrials.gov/.
Regulatory Approval and Reimbursement
Focused ultrasound treatment for COVID is not yet approved by regulatory bodies or covered by medical insurance companies.
Notable Papers
Rasouli R, Hartl B, Konecky SD. Low-intensity ultrasound lysis of amyloid microclots in a lab-on-chip model. Front Bioeng Biotechnol. 2025 Jun 30;13:1604447. doi: 10.3389/fbioe.2025.1604447. eCollection 2025. PMID: 40661336
Click here for additional references from PubMed.